Novartis eyes filings for leukaemia drug asciminib after phase 3 winA first-in-class STAMP inhibitor developed by Novartis – asciminib – has outperformed a current drug for chronic myeloid Share XNovartis eyes filings for leukaemia drug asciminib after phase 3 winhttps://pharmaphorum.com/news/novartis-eyes-filings-for-leukaemia-drug-asciminib-after-phase-3-win/
